Skip to main content

Table 1 Phase 3 trials of chemotherapy in previously untreated CLL patients

From: Therapeutic advancement of chronic lymphocytic leukemia

Reference (year) Regimen Number of patients Median age (years) CR,% ORR,% Median PFS (months) OS
Rai, 2000 [4] Chlorambucil 181 62 4 37 14 Median 56 m
  Fludarabine 170 64 20 63 20 Median 66 m
Eichhorst, 2009 [5] Chlorambucil 100 70 0 51 18 Median 64 m
  Fludarabine 93 71 7 72 19 Median 46 m
Knauf, 2009 [7] Chlorambucil 157 66 2 31 8.3 NR
  Bendamustine 162 63 31 68 21.6 NR
Eichhorst, 2006 [9] Fludarabine 164 59 7 83 20 81% at 3 y
  FC 164 58 24 94 48 80% at 3 y
Catovsky, 2007 [10] Fludarabine 194 64 15 80 23 52% at 5 y
  FC 196 65 38 94 43 54% at 5 y
  Chlorambucil 387 65 7 72 20 59% at 5 y
Flinn, 2007 [11] Fludarabine 137 61 5 60 19 80% at 2 y
  FC 141 61 23 74 32 79% at 2 y
Robak, 2010 [13] CC 192 58 47 88 28 62.4% at 4 y
  FC 203 59 46 82 27 60.6% at 4 y
Robak, 2011 [15] Cladribine 174 61 21 78 27.2 Median 45 m
  CC 171 62 29 83 22.4 Median 48 m
  CMC 163 59 36 80 25.6 Median 46 m
  1. Abbreviations: CC, cladribine, cyclophosphamide; CMC, cladribine, cyclophosphamide, mitoxantrone; CR, complete response; FC, fludarabine, cyclophosphamide; NR, not researched; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.